UnknownPhase 4

Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus

Taiwan120 participantsStarted 2010-12-29

Plain-language summary

To investigate the efficacy of using antiviral therapy in third trimester of pregnancy to reduce mother-to-infant HBV transmission, and to access the safety of such treatment for mothers and infants.

Who can participate

Age range20 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Women aged 20-45 years in 28 to 32 weeks of pregnancy * Positive HBsAg and HBeAg * Serum viral load above 6 log10 IU/mL Exclusion criteria: * Major systemic disease of the mother or fetus * Positive anti-HIV or anti-HCV * Under treatment of antiviral therapy * Pregnant woman whose ultrasonographic examination reveals congenital anomaly of the fetus * Pregnant woman whose amniocentesis reveals any genetic abnormality

What they're measuring

Child HBsAg 6 mo

Timeframe: 6 months after delivery

Trial details

NCT IDNCT03695029

SponsorNational Taiwan University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-31

Contact for this trial

Mei-Hwei Chang

+886-2-23123456 changmh@ntu.edu.tw

View on ClinicalTrials.gov More Hepatitis B Virus Infection trials